Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.

Abraham Saborido-AlconchelAna Serna-GallegoLuis Eduardo Lopez-CortesMaría Trujillo-RodriguezJuan Manuel Praena-FernandezMontserrat Dominguez-MaciasCarmen LozanoEsperanza Muñoz-MuelaNuria EspinosaCristina Roca-OportoCesar SotomayorMarta HerreroAlicia Gutiérrez-Valencia Luis Fernando López-Cortés

Published in: The Journal of antimicrobial chemotherapy (2023)

After 12 weeks of treatment, there were no differences in the percentage of undetectable SP HIV-1-RNA in naive PLWH who started dolutegravir/lamivudine compared with DTG + TAF/FTC.

Keyphrases

antiretroviral therapy
hiv infected
hiv infected patients
hiv positive
human immunodeficiency virus
hiv aids
hepatitis c virus
replacement therapy